The efficacy and safety of anti-PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.

被引：0
|
作者：
Chen, Jiaying
Ji, Qinghai
Wang, Yu
Huang, Naisi
Hu, Jiaqian
Wei, Wenjun
Huang, Caiping
Shen, Qiang
Li, Duanshu
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Head & Neck Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6084
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.
    Liu, Jieqiong
    Jiang, Zefei
    Li, Qian
    Li, Ying
    Liu, Qiang
    Song, Erwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
    Jia, R.
    Li, Y. L.
    Jin, Y. S.
    Chen, Y.
    Zhang, Y.
    Wan, Y.
    Liu, R. R.
    Zhou, H.
    Jiang, Y. B.
    Xu, Q.
    Xu, J. M.
    NEUROENDOCRINOLOGY, 2018, 106 : 230 - 230
  • [43] Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Bao, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
    Kindler, Hedy Lee
    Karrison, Theodore
    Khattri, Arun
    Zuo, Zhixiang
    Sulai, Nanna
    Rose, Buerkley
    Ahmad, Mehwish I.
    Armato, Samuel
    Salgia, Ravi
    Seiwert, Tanguy
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S630 - S630
  • [45] EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY
    Chen, Bowen
    Zhang, Linzhi
    Cheng, Jiamin, Sr.
    Yan, Tao
    Lu, Yinying
    HEPATOLOGY, 2021, 74 : 637A - 638A
  • [46] Efficacy and safety of neoadjuvant chemoradiotherapy combined with tislelizumab and thymalfasin in the treatment of locally advanced lower rectal cancer
    Yao, Hongwei
    Gao, Jiale
    Yang, Zhengyang
    Sun, Liting
    Wei, Pengyu
    Wu, Si
    Meng, Cong
    Xu, Rui
    Chen, Guangyong
    Wu, Guocong
    Bai, Zhigang
    Zhang, Zhongtao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study
    Fan, Yiqun
    Zhu, Xiaoling
    Xu, Chengcai
    Ding, Caiyou
    Hu, Jibo
    Hong, Qiang
    Wang, Jianwei
    BMJ OPEN, 2023, 13 (03):
  • [48] Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study
    Zhou, F.
    Yang, L.
    Peng, J.
    Xu, H.
    Wu, H.
    Wang, Y.
    Long, X.
    Gao, Q.
    Shi, X.
    Gong, J.
    Hu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S668 - S668
  • [49] Phase II clinical trial to study the safety and efficacy of combined S-1+oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients
    Ota, Mitsuhiko
    Saeki, Hiroshi
    Uehara, Hideo
    Matsuda, Yoshiko
    Tsutsumi, Satoshi
    Kusumoto, Tetsuya
    Yasui, Hisateru
    Ubukata, Yasunari
    Yamaguchi, Shohei
    Orita, Hiroyuki
    Izawa, Naoki
    Kakizoe, Saburo
    Shimokawa, Mototsugu
    Yoshizumi, Tomoharu
    Kakeji, Yoshihiro
    Mori, Masaki
    Oki, Eiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (09) : 1166 - 1175
  • [50] Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients
    Mitsuhiko Ota
    Hiroshi Saeki
    Hideo Uehara
    Yoshiko Matsuda
    Satoshi Tsutsumi
    Tetsuya Kusumoto
    Hisateru Yasui
    Yasunari Ubukata
    Shohei Yamaguchi
    Hiroyuki Orita
    Naoki Izawa
    Saburo Kakizoe
    Mototsugu Shimokawa
    Tomoharu Yoshizumi
    Yoshihiro Kakeji
    Masaki Mori
    Eiji Oki
    International Journal of Clinical Oncology, 2023, 28 : 1166 - 1175
12345